Our Services/Product Lifecycle/

Feasibility & Site Selection

Precision Site Selection For Protocol-Ready Performance

Get in touch

Baupharma provides feasibility and site selection services designed to strengthen study planning at the earliest stage of clinical development.

The focus is on identifying the countries, sites, and investigators most capable of delivering against protocol requirements, enrolment goals, and operational timelines.

By combining therapeutic insight with operational analysis, the service supports more informed placement decisions and reduces the risk of underperforming sites later in the study.

Built Around The Protocol

Each feasibility assessment is built around the specific demands of the protocol. This approach gives sponsors a more realistic view of expected recruitment conditions and operational readiness before commitments are made.

Quality by design principles are evaluated to determine whether the proposed study can be executed effectively in a given market or site network.

Patient Population Access
Competing Studies
Standard-Of-Care Considerations
Investigator Interest
Site Infrastructure

Site selection is approached as both Scientific & Operational Exercise.

This creates a stronger foundation for activation and helps ensure that selected sites are positioned to contribute meaningfully once the trial begins.

Centres are reviewed for

Previous Research Performance

Pharmacy & Laboratory Capabilities

Staffing Capacity

Internal Workflows

Alignment With Study Complexity

Through a disciplined and data-informed methodology,

Baupharma helps sponsors move forward with greater confidence, clearer assumptions, and a study footprint designed for performance.

Next in Product Lifecycle

Data Management & Biostatistics

Reliable, Analysis-Ready Clinical Data

Ready To Simplify Your Journey?

Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.

Request Free Consultation Submit RFI/RFP

No commitment required
48h response time